BioCardia Inc is a leading biotechnology company focused on cardiovascular therapies. The company values innovation, patient-centricity, and collaboration in its pursuit of developing novel treatments for heart diseases. BioCardia is committed to advancing and commercializing cutting-edge medical technologies that improve the lives of patients globally. With a strong corporate philosophy rooted in scientific research, BioCardia aims to revolutionize the field of cardiovascular medicine by delivering breakthrough therapies and solutions. By leveraging its expertise and strategic partnerships, BioCardia strives to make a significant impact in the treatment landscape and ultimately contribute to better patient outcomes.

BioCardia Inc is primarily present in the United States.

BioCardia Inc, a leading medical technology company, has achieved several significant milestones. Notably, the company successfully completed the CardiAMP Heart Failure Trial, demonstrating the safety and efficacy of their CardiAMP cell therapy in treating heart failure patients. Furthermore, BioCardia received FDA Breakthrough Device Designation for their investigational CardiAMP Chronic Myocardial Ischemia Trial, highlighting the innovative nature and potential impact of their therapy for chronic myocardial ischemia patients. In addition, the company has secured multiple patents, reinforcing their commitment to developing groundbreaking solutions. These achievements underscore BioCardia Inc's position as a pioneering force in the field of regenerative medicine dedicated to improving cardiac care.

BioCardia Inc is a medical technology company based in San Carlos, California. Founded in 2004, BioCardia specializes in developing innovative solutions for cardiovascular diseases. The company focuses on advanced therapies to treat heart failure, ischemic heart disease, and certain cardiovascular conditions. BioCardia is dedicated to improving patient outcomes by providing minimally invasive treatments that enhance the heart's ability to heal itself. With a team of experienced professionals and a commitment to research and development, BioCardia continues to advance its portfolio of products and technologies. Over the years, BioCardia has gained recognition as a leading player in the cardiovascular therapies market.

The main competitors of BioCardia Inc in the market include medical device companies such as Boston Scientific Corporation, Medtronic plc, Abbott Laboratories, and Edwards Lifesciences Corporation.

BioCardia Inc is primarily active in the healthcare industry.

The business model of BioCardia Inc is focused on developing and commercializing innovative therapeutics for cardiovascular diseases. They specialize in advanced delivery technologies and biological solutions to treat heart-related conditions. BioCardia Inc aims to provide cutting-edge medical technologies, including cardiac delivery methods and regenerative medicine, to improve patient outcomes in the field of cardiology. With a strong emphasis on research and development, the company strives to create effective and safe treatment options for individuals suffering from cardiovascular ailments. Overall, BioCardia Inc operates with the goal of revolutionizing cardiovascular care through its innovative business model and dedication to improving patient lives.

BioCardia KGV ir -0,23.

BioCardia KUV ir 8,25.

AlleAktien kvalitātes vērtējums BioCardia ir 5/10.

gaidāmā BioCardia apgrozījums ir 510 000,00 USD.

gaidāmā BioCardia peļņa ir -18,06 milj. USD.

BioCardia Inc is a biopharmaceutical company based in San Carlos, California, USA. The company specializes in the development and commercialization of innovative treatment methods for heart diseases. Business Model and Divisions BioCardia's business model is based on the invention, development, and commercialization of technologies and products for the diagnosis and treatment of heart diseases. The company has three main divisions: products, services, and clinical trials. The first division, products, includes a wide range of products that focus on the treatment of heart diseases. These include catheter-based systems for the administration of cell therapies and biological agents for tissue regeneration. The second division, services, includes a variety of services in the areas of research, development, and clinical trials. These include laboratory and analysis services, as well as consulting services for pharmaceutical and biotech companies. The third division, clinical trials, is also a key strategic pillar of BioCardia. The company conducts extensive clinical research to evaluate the effectiveness and safety of its products and technologies. Core Products One of BioCardia's key products is the CardiAMP system, which contains autologous bone marrow-concentrated/stromal cells (BMCC/MSC) that are used for the regeneration of heart muscle tissue. It consists of a special catheter that extracts a patient's blood, which is then processed and reinjected into the heart. Another important product is the Helix system, which is used to treat patients with coronary artery disease. It consists of a flexible catheter that is inserted into the artery to improve blood flow and support the cardiovascular system. Strategic Partnerships BioCardia has also formed strategic partnerships with other companies and medical institutions to accelerate and strengthen its research and development efforts. For example, the company has announced a collaboration with Mayo Clinic and Boston Scientific Corp. as part of a research project on novel treatment for heart attacks. Conclusion Overall, BioCardia Inc is a leading company in cardiovascular research and development. The company offers a wide range of products and services that are used for the diagnosis and treatment of heart diseases. With its innovative technologies and comprehensive clinical trials, BioCardia makes a significant contribution to improving the medical care of patients with cardiovascular diseases.

BioCardia izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt BioCardia vai uzņēmums nedod dividendes.

BioCardia ISIN ir US09060U5074.

BioCardia WKN ir A2PLXH.

BioCardia simbols ir BCDA.

Pēdējo 12 mēnešu laikā BioCardia maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos BioCardia plāno maksāt dividendes 0 USD apmērā.

BioCardia pašreizējā dividendu rentabilitāte ir .

BioCardia maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

BioCardia pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

BioCardia tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu BioCardia apmērā 0 USD, kas tika izmaksāta 20.09.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 20.09.2024..

Pēdējās dividendes izmaksa notika 20.09.2024..

Gadā 2023, BioCardia izmaksāja 0 USD dividendes.

BioCardia dividendes tiek izmaksātas USD.